bluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobinTM Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia Read more about bluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobinTM Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Alliance for Regenerative Medicine’s 6th Annual Cell & Gene Therapy Investor Day Read more about Alliance for Regenerative Medicine’s 6th Annual Cell & Gene Therapy Investor Day
bluebird bio to Present at Alliance for Regenerative Medicine’s 6th Annual Cell & Gene Therapy Investor Day Read more about bluebird bio to Present at Alliance for Regenerative Medicine’s 6th Annual Cell & Gene Therapy Investor Day
bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States Read more about bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States
bluebird bio to Present at Investor Conferences in March Read more about bluebird bio to Present at Investor Conferences in March
Cowen and Company 38th Annual Health Care Conference Read more about Cowen and Company 38th Annual Health Care Conference
Barclays Global Healthcare Conference 2018 Read more about Barclays Global Healthcare Conference 2018
bluebird bio Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress Read more about bluebird bio Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress
bluebird bio Appoints Alison Finger as Chief Commercial Officer Read more about bluebird bio Appoints Alison Finger as Chief Commercial Officer